US 11,906,520 B2
Composition and methods for detecting cancer
Valérie Molinier Frenkel, Saint Maur des Fossés (FR); and Flavia Castellano, Antony (FR)
Assigned to Centre National De La Recherche Scientifique, Paris (FR); Institut National De La Sante Et De La Rech. Med., Paris (FR); and Universite Paris Est Creteil Val DeMarne, Créteil (FR)
Filed by CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR); and UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, Créteil (FR)
Filed on Nov. 22, 2019, as Appl. No. 16/692,574.
Claims priority of application No. 18306563 (EP), filed on Nov. 23, 2018.
Prior Publication US 2020/0166512 A1, May 28, 2020
Int. Cl. G01N 33/574 (2006.01); C07K 16/24 (2006.01)
CPC G01N 33/57484 (2013.01) [C07K 16/247 (2013.01); C07K 2317/565 (2013.01)] 8 Claims
 
1. An isolated monoclonal antibody comprising:
a heavy chain comprising variable domain CDR sequences comprising:
(a) a H-CDR1 comprising the sequence of SEQ ID NO: 8,
(b) a H-CDR2 comprising the sequence of SEQ ID NO: 9 or SEQ ID NO: 18, and
(c) a H-CDR3 comprising the sequence of SEQ ID NO: 10 or SEQ ID NO: 19; and
a light chain comprising variable domain CDR sequences comprising:
(a) a L-CDR1 comprising the sequence of SEQ ID NO: 5,
(b) a L-CDR2 comprising the sequence of SEQ ID NO: 6 or SEQ ID NO: 14, and
(c) a L-CDR3 comprising the sequence of SEQ ID NO: 7 or SEQ ID NO: 15.